Navigation Links
Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
Date:7/18/2011

AUSTIN, Texas, July 18, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the second quarter of 2011 on Monday, August 8, 2011.  A press release announcing the results is scheduled for release after the close of trading.

(Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and financial results for the second quarter and six months ended June 30, 2011, at 5:00 p.m. Eastern time on August 8, 2011.

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the website, go to the About Us section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software.  If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts.  If you use this software, press and hold the CTRL key when you click on the Register button.  Please contact your IT group if you are unable to override this feature.  Unauthorized recording or downloading of this event is not permitted.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.

Statements made in this release that express Luminex Corporation's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Luminex Corporate Contact:
Harriss T. Currie
Chief Financial Officer and Vice President, Finance
512-219-8020
hcurrie@luminexcorp.com

Luminex Investor Relations Contact:
Matthew D. Scalo
Sr. Director of Investor Relations
512-219-8020
mscalo@luminexcorp.com



'/>"/>
SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
2. Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System
3. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
4. Luminex and Life Technologies Sign Agreement for Global Distribution of the Award-Winning MAGPIX® Multiplexing Instrument
5. Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference
6. Luminex Corporation Reports First Quarter 2011 Results
7. Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011
8. Luminex Corporation Wins Prestigious Medical Design Excellence Award
9. Luminex Corporation to Present at Cowen and Companys 31st Annual Health Care Conference
10. Luminex Corporation Ranked One of the 25 Fastest-Growing Technology Companies in America by Forbes for Third Consecutive Year
11. Luminex and Partners HealthCare Announce Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Global Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, ... 2024" report to their offering. ... The global pharmacogenomics market was valued at US$ ... 11,938.8 Mn by 2024, expanding at a CAGR of 5.6% ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
Breaking Medicine Technology:
(Date:4/26/2017)... Houston, TX (PRWEB) , ... April 26, 2017 ... ... open data set that describes the adoption of e-prescribing as measured in Part ... different individual prescribers deliver prescriptions to pharmacies, either using e-prescribing, faxes or paper. ...
(Date:4/26/2017)... ... , ... Miami native and local periodontist Dr. John Paul Gallardo ... back in 1991 that this journey would have taken me into so many learning ... Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally recognized leader in ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... performance, is proud to announce that it has received 510(k) clearance from the ... MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling systems ...
(Date:4/25/2017)... ... 25, 2017 , ... A stressful work environment can hurt the physical and ... and performance in the workplace. The goal of Clearview Resolution Services has always been ... April, Clearview Resolution Services will be shutting down the office early on Fridays. The ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... modern procedure that achieves results in a fraction of the time as traditional ... NV, with Significance Dental Specialists, now offers this revolutionary treatment with or without ...
Breaking Medicine News(10 mins):